Novartis AG (NYSE:NVS) Q4 2025 Earnings Call Transcript February 4, 2026 Novartis AG beats earnings expectations. Reported ...
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance ...
With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...
Are you interested in lowering your risk of developing Alzheimer’s disease and other types of dementia? We can take actions ...
Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.
Net sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong ...
Certain anti-inflammatory supplements may help reduce pain and inflammation caused by conditions like arthritis.
The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of ...
As the management landscape of primary biliary cholangitis (PBC) changes, new second-line options offer effective alternatives for patients who respond inadequately to standard first-line treatment ...
Gene therapy drugs have the potential to cure some diseases, but some have a price tag of over a million dollars. Who gets access to them and who doesn't?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results